Summary: New UCLA-led research shows that blocking an overactive mTOR signaling pathway quickly calms hyperexcitable neurons, restores disordered functional brain networks, and reduces repetitive and sensory-overresponsive behaviors in adult mice exposed to prenatal inflammation. Effects appeared within roughly two hours, a timeframe too brief to reflect structural repair, indicating that adult brains retain substantial functional plasticity even when developmental structural differences persist.
Although rapamycin itself is not appropriate for human clinical use because of limited duration of benefit, tolerance with repeated dosing, and potential toxicity, the study identifies actionable therapeutic targets: neuronal excitability, mTOR-driven signaling, and sensory circuit neuromodulation.
Key Facts
- Rapid functional reversal: One acute dose of rapamycin normalized abnormal neuronal firing, reduced seizure susceptibility, reestablished more typical functional network connectivity, and lessened repetitive behaviors in adult mouse offspring within about two hours.
- Functional versus structural plasticity: The two-hour rescue window is too brief for large-scale structural rewiring, demonstrating that adult neural circuits can be functionally rebalanced without correcting early developmental anatomic differences.
- mTOR and ion channel gene regulation: Gene-expression analysis showed fast reversal of abnormal transcription linked to autism, epilepsy, and ion channel function, particularly in excitatory neurons.
- Maternal immune activation model: Mild maternal inflammation during early gestation produced chronic systemic and brain inflammation, mild brain overgrowth, and lifelong sensory over-responsivity in offspring.
- Translational direction: Rather than promoting rapamycin for human use, findings point toward developing safer approaches that rebalance excitation/inhibition and modulate sensory circuits.
Source: UCLA
Overview: A new mouse study led by UCLA Health indicates that inflammation during pregnancy can produce autism-like brain and behavioral outcomes in offspring, but that many of those functional changes can be rapidly and temporarily normalized in adulthood by an acute dose of the immunosuppressant rapamycin.
Mild maternal inflammation in mid-gestation has been associated with offspring outcomes including repetitive behaviors, altered social traits, mild brain overgrowth, seizures, and heightened sensitivity to everyday sensory input that persists into adulthood. In the study published in Nature Communications, UCLA investigators administered a single dose of rapamycin to adult offspring of mothers exposed to a low-level inflammatory trigger and observed broad improvements in brain signaling and behavior within roughly two hours.
The research team emphasized that rapamycin is not recommended as a human treatment because its benefits were transient, tolerance developed with repeated dosing, and it carries toxicity risks. Instead, the drug served as an experimental tool to reveal mechanisms and identify targets that could inform safer, targeted therapies.
“The degree of functional normalization in such a short timeframe points to mechanisms that could be harnessed therapeutically,” said Dr. Harley Kornblum, director of the UCLA Intellectual and Developmental Disabilities Research Center. “It suggests the adult brain may be more adaptable than previously thought, and highlights functional circuitry as a treatment target in addition to physical structure.”
To create the model, researchers exposed pregnant mice to a mild immune-activating stimulus early in gestation at a dose that did not make the mothers severely ill. Their offspring developed chronic systemic and brain inflammation, moderate brain enlargement in specific regions, overactivation of the mTOR cell-signaling pathway, disrupted functional network connectivity, and behaviors consistent with autism-spectrum features, including sensory over-responsivity and repetitive actions.
After a single acute rapamycin dose in adulthood, the investigators measured fast, widespread changes: previously hyperactive neurons reduced their firing, seizure susceptibility declined, brain regions that had been miscommunicating showed more typical functional organization, and repetitive and sensory-overresponsive behaviors diminished. Because these effects appeared within approximately two hours, the team concluded they resulted from rapid changes in neuronal signaling and network dynamics rather than from structural synaptic remodeling.
First author Dr. Janel Le Belle noted, “If the adult brain can be functionally normalized, some autism-associated features might be addressed without needing to reverse early structural differences. That opens new avenues for treating specific symptoms.”
To probe mechanisms, the team performed gene-expression profiling of brain cells before and after rapamycin. The drug rapidly reversed dysregulated genes linked to autism, epilepsy, and ion channel activity—effects strongest in excitatory neurons—supporting the idea that correcting excitability imbalances underlies the behavioral improvements.
Co-senior author Dr. Neil Harris cautioned that daily rapamycin dosing produced tolerance over several weeks in mice and carries safety concerns, underscoring why the compound itself is not a clinical solution. Instead, the results redirect research toward safer strategies such as sensory circuit neuromodulation and therapies that restore excitatory/inhibitory balance.
Key Questions Answered
A: Maternal immune activation can produce lasting brain inflammation, heightened mTOR signaling, altered gene expression in excitatory neurons, disrupted functional connectivity, and lifelong sensory sensitivity with autism-like behaviors.
A: Improvement within two hours is too rapid to be explained by structural synapse remodeling, indicating that behavioral and network dysfunctions are driven by real-time signaling imbalances that can be functionally corrected in adults.
A: No. Rapamycin’s effects were temporary in this mouse study, tolerance emerged with repeated dosing, and the drug has significant toxicity risks. The primary value of these results is guiding development of safer, targeted interventions that rebalance neuronal excitation and sensory circuits.
Editorial Notes
- Edited by Neuroscience News staff.
- Journal paper reviewed in full by editors.
- Additional context added by editorial staff.
About this autism research news
Author: Will Houston
Source: UCLA
Contact: Will Houston – UCLA
Image: The image is credited to Neuroscience News
Original Research: Open access. “Acute rapamycin treatment reveals distinct mechanisms of dysfunction in a maternal inflammation mouse model” by JE Le Belle et al., published in Nature Communications. DOI: 10.1038/s41467-026-74958-1
Abstract
Acute rapamycin treatment reveals distinct mechanisms of dysfunction in a maternal inflammation mouse model
Maternal inflammatory response during early gestation in mice produces physiological and behavioral changes associated with autism spectrum disorder (ASD). Mild maternal inflammation leads to chronic systemic and brain inflammation, activation of the mTOR signaling pathway, mild region-specific brain overgrowth, sensory processing dysregulation, and repetitive behavior abnormalities.
Previous rapamycin research has focused on chronic treatments that can alter or prevent structural brain changes. This study examined acute rapamycin effects to identify rapid, mTOR-mediated mechanisms of dysfunction. Within two hours, rapamycin reversed neuronal hyperexcitability, reduced seizure susceptibility, restored functional network connectivity and brain community structure, and alleviated repetitive behaviors and sensory over-responsivity in adult offspring exposed to maternal inflammation.
These central nervous system effects coincided with corrected expression of genes linked to ASD, ion channels, and epilepsy. The results indicate that mTOR dysregulation drives developmental dysfunction yet the adult brain remains capable of rapid functional normalization, suggesting that restoring excitation/inhibition balance and sensory network modularity may be promising therapeutic targets for multiple ASD-related phenotypes.